Delmitide
Delmitide has been in phase II clinical trials for the treatment of crohn's disease and ulcerative colitis. This compound was originally discovered by Genzyme, then licensed to Procter & Gamble in 2004. However, no recent development has been reported.
General Information
Update Date：2016-01-18
- Drug Name：
- Delmitide
- Research Code：
- Allotrap-1258; Rationally Designed Peptide 58; RDP-1258; RDP-58
- Trade Name：
- MOA：
- IL-12 production inhibitor；TNF-alpha production inhibitor； IFN-gamma production inhibitor
- Indication：
- Crohn's disease; Ulcerative colitis
- Status：
- Phase II (Pending)
- Company：
- Genzyme (Originator) , Procter & Gamble
- Sales：
- ATC Code：
Chemical Structure
Update Date：2016-01-18
|
Molecular Weight | 1228.57 | ||||||||||||
| Formula | C59H105N17O11 | |||||||||||||
| CAS No. | 287096-87-1 (Delmitide); | |||||||||||||
| Chemical Name | D-Tyrosinamide, D-arginyl-D-norleucyl-D-norleucyl-D-norleucyl-D-arginyl-D-norleucyl-D-norleucyl-D-norleucylglycy | |||||||||||||
| Delmitide （Free Acid/Base）Parameters： | ||||||||||||||
|
||||||||||||||
| *：Calculated by ACD/Labs software V11.02. | ||||||||||||||